{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-212769","form_type":"8-K","ticker":null,"cik":"0000811240","company_name":"BIOLASE, INC","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.705811+00:00","generated_at":"2026-06-11T09:48:59.340476+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BIOLASE avoids Nasdaq delisting but faces one-year Mandatory Panel Monitor for bid price compliance","bullets":["Nasdaq Hearings Panel confirmed BIOLASE currently complies with continued listing requirements.","Company subject to a one-year Mandatory Panel Monitor starting August 14, 2023.","If bid price rule violated during monitor, no cure period allowed; staff issues delist determination.","Company can request a new hearing if delist determination is issued."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-212769","json":"https://secwatch.observer/filing/0001193125-23-212769.json","markdown":"https://secwatch.observer/filing/0001193125-23-212769.md","text":"https://secwatch.observer/filing/0001193125-23-212769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811240/000119312523212769/0001193125-23-212769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811240/000119312523212769/d521897d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:48:59.340476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80abfb7e3e006ec05db8b83d1209108820f6bc76","claim":"BIOLASE, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5815(d)(4)(B), 5550(a)(2), 5810(c)(2), 5810(c)(3), 5815(d)(4)(C)).","evidence_excerpt":"August 14, 2023, BIOLASE, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Office of General Counsel confirming the decision of the Nasdaq Stock Market LLC (“Nasdaq”) Hearings Panel (the “Panel”), that the Company currently demonstrates compliance with the requirements for continued listing on The Nasdaq Capital Market. According to the Letter, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from the date of this letter. If, within that one-year monitoring period, the Listing Qualifications st","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/811240/000119312523212769/0001193125-23-212769-index.htm","confidence":0.82,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5815(d)(4)(B), 5550(a)(2), 5810(c)(2), 5810(c)(3), 5815(d)(4)(C)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}